Rituximab in combination with multiagent chemotherapy for Pediatric follicular lymphoma

Riten Kumar, Paul J. Galardy, Ahmet Dogan, Vilmarie Rodriguez, Shakila P. Khan

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Given the rarity of follicular lymphoma (FL) in children, there is limited data on which to base treatment recommendations. Herein, we report our institutional experience of using rituximab with multiagent chemotherapy for pediatric FL. Six pediatric patients were diagnosed with FL from 2000 to 2009. All patients received rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for varying durations. Five of the six patients remain in remission with a median follow-up of 31 months. Larger randomized trials are indicated to establish the efficacy of this regimen for pediatric FL patients.

Original languageEnglish (US)
Pages (from-to)317-320
Number of pages4
JournalPediatric Blood and Cancer
Volume57
Issue number2
DOIs
StatePublished - Aug 1 2011

Keywords

  • Follicular lymphoma
  • Rituximab

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Rituximab in combination with multiagent chemotherapy for Pediatric follicular lymphoma'. Together they form a unique fingerprint.

  • Cite this